Cognitive neuroenhancement: False assumptions in the ethical debate

Journal of Medical Ethics

Volumn 38, Issue 6, 2012, Pages 372-375

  Heinz, Andreas ^a   Kipke, Roland ^a,b   Heimann, Hannah ^a   Wiesing, Urban ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CENTRAL STIMULANT AGENT;

ADDICTION; ARTICLE; CHEMICALLY INDUCED DISORDER; COGNITION; DRUG EFFECT; ETHICS; HUMAN; MEDICAL TECHNOLOGY; METHODOLOGY; NEUROSCIENCE; PSYCHOLOGICAL ASPECT; RISK FACTOR;

BEHAVIOR, ADDICTIVE; BIOMEDICAL ENHANCEMENT; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; HUMANS; NEUROSCIENCES; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84863996706     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/medethics-2011-100041     Document Type: Article

References (39)

1. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature 2008;456:702-5.
2. DAK. Gesundheitsreport 2009. Analyse der Arbeitsunfähigkeitsdaten. Schwerpunktthema Doping am Arbeitsplatz. 2009. http://www.dak.de/content/filesopen/Gesundheitsreport_2009.pdf (accessed 2 Mar 2011).
3. Lohse KJ, Müller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Paffrath D, eds. Arzneiverordnungs-Report 2009. Aktuelle Daten, Kosten, Trends und Kommentare. Heidelberg: Springer, 2009:798.
4. Lieb K. Hirndoping: Warum wir nicht alles schlucken sollten. Mannheim: Artemis & Winkler, 2010.
5. Galert T, Bublitz C, Heuser I, et al. Das optimierte Gehirn. Gehirn & Geist 2009. http://www.wissenschaft-online.de/sixcms/media.php/976/Gehirn_und_Geist_Memorandum.pdf (accessed 2 Mar 2011).
6. Heinz A, Beck A, Grüsser SM, et al. Identifying the neural circuitry of alcohol craving and relapse vulnerability. Addict Biol 2009;14:108-18.
7. Hyman SE. Addiction: a disease of learning and memory. Am J Psychiatry 2005;162:1414-22.
8. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162:1403-13.
9. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005;8:1481-9.
10. Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005;8:147-8.
11. Di Chiara G, Bassareo V. Reward system and addiction: what dopamine does and doesn't do. Curr Opin Pharmacol 2007;7:69-76.
12. Park SQ, Kahnt T, Beck A, et al. Prefrontal cortex fails to learn from reward prediction errors in alcohol dependence. J Neurosci 2010;30:7749-53.
13. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004;9:557-69.
14. Martel P, Fantino M. Influence of the amount of food ingested on mesolimbic dopaminergic system activity: a microdialysis study. Pharmacol Biochem Behav 1996;55:297-302.
15. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology 2002;27:182-93.
16. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274-8.
17. Hyman SE. The neurobiology of addiction: implications for voluntary control of behaviour. Am J Bioeth 2007;7:8-11.
18. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-54.
19. 2010 European Medicines Agency (EMA). European Medicines Agency Recommends Restricting the Use of Modafinil. Press Release. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/07/WC500094976.pdf (accessed 11 Nov 2011).
20. Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work. Am J Psychiatry 2005;162:1983.
21. Pélissier-Alicot AL, Piercecchi-Marti MD, Bartoli C, et al. Abusive prescreption of psychostimulants: a study of two cases. J Forensic Sci 2006;51:407-10.
22. Heinz A, Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr Bull 2010;36:472-85.
23. Tarrant N, Cavanna AE, Rickards H. Pathological gambling associated with modafinil. J Neuropsychiatry Clin Neurosci 2010;22:123.E27-8.
24. Di Chiara G. The role of dopamine in drug abuse viewed from the perspective of its role in motivation. Drug Alcohol Depend 1995;38:95-137.
25. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res 2002;137:75-114.
26. Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science 1997;275:1593-9.
27. Montague PR, Hyman SE, Cohen JD. Computational roles for dopamine in behavioural control. Nature 2004;431:760-7.
28. Schlagenhauf F, Rapp MA, Huys QJM, et al. Ventral striatal prediction error signaling is associated with dopamine synthesis capacity and fluid intelligence. Hum Brain Mapp. Published Online First: 17 Feb 2012. doi:10.1002/hbm.22000.
29. Heinz A, Siessmeier T, Wrase J, et al. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry 2005;162:1515-20.
30. Heinz A, Dufeu P, Kuhn S, et al. Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry 1996;53:1123-8.
31. Wiesing U. Wer heilt, hat Recht? Über Pragmatik und Pluralität in der Medizin. Stuttgart: Schattauer, 2004.
32. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
33. Marckmann G. Priorisierungen im Gesundheitswesen: was können wir aus den internationalen Erfahrungen lernen? Z Evid Fortbild Qual Gesundhwes 2009;103:85-91.
34. Zentrale Kommission zur Wahrung ethischer Grundsätze in der Medizin und ihren Grenzgebieten (Zentrale Ethikkommission) bei der Bundesärztekammer. Stellungnahme zur Priorisierung medizinischer Leistungen im System der Gesetzlichen Krankenversicherung (GKV). Dtsch Ärztebl 2007;104:A-2750-4.
35. Buchanan A. Beyond Humanity? The Ethics of Biomedical Enhancement. New York: Oxford University Press, 2011.
36. Savulescu J, ter Meulen R, Kahane G. Enhancing Human Capacities. Malden, Massachusetts: Blackwell Publishing, 2011.
37. Herrnstein RJ, Murray C. The Bell Curve: Intellegence and Class Structure in American Life. New York: The Free Press, 1996.
38. Flynn JR. Massive IQ gains in 14 nations: what IQ tests really measure. Psychol Bull 1987;101:171-91.
39. Kipke R. Besser werden. Eine ethische Untersuchung zu Selbstformung und Neuro-Enhancement. Paderborn: mentis, 2011.